维昇药业-B(02561)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02561 维昇药业-B

已收盘 04-25 16:08:23

47.800

+0.200

+0.42%

最高50.000	最低47.700	成交量8.76万
今开48.950	昨收47.600	日振幅4.83%
总市值54.49亿	流通市值54.49亿	总股本1.14亿
成交额432.65万	换手率0.08%	流通股本1.14亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02561","market":"HK","secType":"STK","nameCN":"维昇药业-B","latestPrice":47.8,"timestamp":1745568503017,"preClose":47.6,"halted":0,"volume":87600,"delay":0,"floatShares":113999999,"shares":113999999,"eps":-26.719126,"marketStatus":"已收盘","change":0.2,"latestTime":"04-25 16:08:23","open":48.95,"high":50,"low":47.7,"amount":4326455,"amplitude":0.048319,"askPrice":48.4,"askSize":500,"bidPrice":47.8,"bidSize":400,"shortable":0,"etf":0,"ttmEps":-18.277715,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1745803800000},"marketStatusCode":5,"adr":0,"listingDate":1742486400000,"exchange":"SEHK","adjPreClose":47.6,"openAndCloseTimeList":[[1745544600000,1745553600000],[1745557200000,1745568000000]],"volumeRatio":0.890425,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02561","defaultTab":"news","newsList":[{"id":"2529457811","title":"维升药业-B04月23日主力净流入333万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2529457811","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529457811?lang=zh_cn&edition=full","pubTime":"2025-04-23 16:17","pubTimestamp":1745396223,"startTime":"0","endTime":"0","summary":"04月23日, 维升药业-B股价涨9.14%，报收48.35元，成交金额1183万元，换手率0.22%，振幅11.40%，量比3.64。维升药业-B今日主力资金净流入333万元，上一交易日主力净流出0万元。该股近5个交易日上涨13.76%，主力资金累计净流入333万元；近20日主力资金累计净流入349万元，其中净流入天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423171341a6c4f2a9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423171341a6c4f2a9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2529546740","title":"港股异动 | 维升药业-B(02561)再涨超11% 隆培促生长素国内上市申请已获受理 预计将于2025年内获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2529546740","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529546740?lang=zh_cn&edition=full","pubTime":"2025-04-23 13:58","pubTimestamp":1745387899,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维升药业-B再涨超11%，截至发稿，涨10.16%，报48.8港元，成交额961.22万港元。目前，隆培促生长素已经完成中国3期关键性试验，国内上市申请已获受理，预计将于2025年内获批。除隆培促生长素之外，其他两个管线产品那韦培肽、帕罗培特立帕肽，分别用于治疗软骨发育不全、甲状旁腺功能减退症。根据2023年9月国家卫生健康委员会发布的第二批《罕见病目录》，软骨发育不全和遗传性甲状旁腺功能减退症均纳入其中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1282977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2529346108","title":"港股异动 | 维升药业-B(02561)涨超7% 核心产品隆培促生长素有望年内获批 生长激素市场规模呈显著增长态势","url":"https://stock-news.laohu8.com/highlight/detail?id=2529346108","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529346108?lang=zh_cn&edition=full","pubTime":"2025-04-22 15:45","pubTimestamp":1745307927,"startTime":"0","endTime":"0","summary":"目前，隆培促生长素已经完成中国3期关键性试验，国内上市申请已获受理，预计将于2025年内获批。国证国际此前指，根据Frost&Sullivan的资料，中国人生长激素市场规模呈现显著的增长态势。公司竞争优势方面，基于经验证技术的研发后期管线，公司拥有快速接近创收的高度确定性；隆培促生长素在全球最大且快速增长的中国人生长激素市场中，是用于PGHD的长效人生长激素替代疗法，目前BLA申报已获国家药监局受理；其他在研产品有序推进。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1282183.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2528123457","title":"维升药业-B(02561)：稳定价格行动、稳定价格期间结束及超额配售权失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2528123457","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528123457?lang=zh_cn&edition=full","pubTime":"2025-04-17 20:47","pubTimestamp":1744894066,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维升药业-B(02561)发布公告，与全球发售有关的稳定价格期间已于2025年4月17日(即递交香港公开发售申请截止日期后第30日)结束。联席全球协调人及整体协调人(代表国际包销商)并无于稳定价格期间行使超额配售权，超额配售权已于2025年4月17日失效。因此，公司并无已或将根据超额配售权发行股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1280396.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02561"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.visenpharma.com","stockEarnings":[{"period":"1week","weight":0.1582},{"period":"1month","weight":-0.2067},{"period":"3month","weight":-0.3081},{"period":"ytd","weight":-0.3081}],"compareEarnings":[{"period":"1week","weight":0.0241},{"period":"1month","weight":-0.0614},{"period":"3month","weight":0.0919},{"period":"6month","weight":0.0641},{"period":"1year","weight":0.2737},{"period":"ytd","weight":0.0922}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"维昇药业是一家主要从事开发并商业化颠覆式内分泌疗法的投资控股公司。该公司的主要在研产品包括隆培促生长素、那韦培肽和帕罗培特立帕肽。隆培促生長素用于治疗3至17岁儿童生长激素缺乏症患者。那韦培肽是一款用于治疗2至10岁软骨发育不全儿童患者的疾病修复疗法。帕罗培特立帕肽是一款用于治疗成人甲状旁腺功能减退症的治疗方法。该公司处于研发后期、产品接近商业化。","exchange":"SEHK","name":"维昇药业-B","nameEN":"VISEN PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"维昇药业-B(02561)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供维昇药业-B(02561)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"维昇药业-B,02561,维昇药业-B股票,维昇药业-B股票老虎,维昇药业-B股票老虎国际,维昇药业-B行情,维昇药业-B股票行情,维昇药业-B股价,维昇药业-B股市,维昇药业-B股票价格,维昇药业-B股票交易,维昇药业-B股票购买,维昇药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"维昇药业-B(02561)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供维昇药业-B(02561)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}